This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Morris J. Wizenberg, MD
Mercy Health Center Oklahoma City

JAMA. 1985;254(8):1032.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Drs Yarbro and Mortenson in their COMMENTARY in the Feb 1 issue of JAMA¹ have correctly identified a critical issue in the care of cancer patients. Unfortunately, they did not stress that many of those patients who are in formal clinical trials are there precisely because the conventional treatment has either already failed or shows little promise of being successful. If those patients cannot be treated either as members of the study population in a clinical trial or with that same treatment in some other context, they may very well receive no effective treatment at all.

Dr Davis'² reply begs the issue. If she will merely take a look, for example, at the diagnosis-related groups' (DRGs) reimbursement for the treatment of acute leukemia, she must immediately recognize that no patient can receive any modern course of treatment with the aim of producing a complete remission without . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Senior Contributing Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?